13 Apr 2021 by admin in UncategorizedComments Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies
13 Apr 2021 by admin in UncategorizedComments Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research
10 Apr 2021 by admin in UncategorizedComments NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR)
06 Apr 2021 by admin in UncategorizedComments Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma
30 Mar 2021 by admin in UncategorizedComments Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters
29 Mar 2021 by admin in UncategorizedComments Tempest and Millendo Announce Proposed Merger Agreement
26 Mar 2021 by admin in UncategorizedComments Design Therapeutics Announces Pricing of Initial Public Offering
